+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07531043

Evaluating Apraclonidine Ophthalmic Solution Compared to Placebo for Adults with Eye Redness A Randomized Double-Blind Study

Led by Alcon Research · Updated on 2026-10-16

230

Participants Needed

9

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the effectiveness and safety of an investigational eye drop solution called Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, compared to a placebo vehicle solution in adults experiencing eye redness due to minor irritations. The study targets adults with ocular redness and focuses on measuring changes in redness after treatment. It is a Phase 3, randomized, double-blind clinical trial sponsored by Alcon Research. Participants will receive a single dose of the study treatment, one drop in each eye on Day 1. The study includes two groups one receiving the investigational Apraclonidine solution and the other receiving a vehicle placebo. The treatment is given during an in-office visit, and eye redness is assessed before and after instillation at specific timepoints on Day 1 and Day 2. Participants are expected to attend three in-office visits over about one week. Assessments include investigator-rated redness scores at baseline and at several times after treatment, including 1 minute, 15 minutes, 14 hours, and 16 hours post-instillation. Safety and efficacy are monitored through these evaluations. The total study period covers from treatment through follow-up assessments, concluding around one week after the first dose.

CONDITIONS

Brief Title

Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults

Research Team

A

Alcon Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here